Condition: Metastatic Prostate Cancer · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.
This description comes directly from the study's public registry record.
Catherine Marshall, MD · 410-955-0231 · chm@jhmi.edu
Maddie Klugman · 410-955-8893 · mklugma2@jh.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07209176